奥泰生物: 关于作废2022年限制性股票激励计划部分限制性股票的公告

Core Viewpoint - The company has announced the cancellation of part of the restricted stock incentive plan from 2022 due to the departure of three incentive recipients, resulting in the cancellation of a total of 6,177 shares that have been granted but not yet vested [8][9]. Summary by Sections 1. Decision Process and Disclosure - The company held a board meeting on June 27, 2022, to approve the draft of the 2022 restricted stock incentive plan and related matters, with independent directors expressing their agreement [1][2]. - The plan was publicly disclosed on June 28, 2022, and the list of initial incentive recipients was announced without any objections from employees [4][5]. 2. Specifics of the Canceled Shares - The cancellation of the restricted stock was due to three recipients leaving the company, which disqualified them from the incentive program, leading to the cancellation of 6,177 shares [8][9]. 3. Impact on the Company - The cancellation of these shares is not expected to have a significant impact on the company's financial status or operational results, nor will it affect the stability of the core team or the ongoing implementation of the incentive plan [8]. 4. Opinions from Supervisory and Compensation Committees - The supervisory board and the compensation and assessment committee both agreed that the cancellation aligns with legal regulations and the incentive plan's provisions, confirming that it does not harm the interests of the company or its shareholders [9][9]. 5. Legal Opinion - The legal firm involved has concluded that the company has fulfilled necessary approvals and disclosures regarding the cancellation, ensuring compliance with relevant regulations [9].